z-logo
Premium
Effects of N 6 ‐cyclohexyladenosine (CHA) on responses to adrenergic and cholinergic nerve stimulation in the peripheral autonomic nervous system
Author(s) -
Kitzen Jan M.,
Schwenkler Mary A.,
Moeller Janice E.,
Hellyer Luther D.,
Wilson Sandy J.
Publication year - 1983
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430030404
Subject(s) - chronotropic , adenosine , stimulation , endocrinology , medicine , bradycardia , chemistry , cholinergic , adrenergic , caffeine , sympathetic nervous system , vagus nerve , heart rate , blood pressure , receptor
The adenosine derivative N 6 ‐cyclohexyladenosine (CHA), was studied in various cardiovascular and autonomic experiments. In hemodynamic studies in dogs, CHA 0.5 mg/kg, i.v., caused moderate hypotension and bradycardia. Additional studies in dogs showed that a portion of the bradycardia was the result of an inhibitory effect on the sympathetic nerves to the heart since the chronotropic reponses to cardioaccelerator nerve stimulation were inhibited while the responses to isoproterenol were slightly potentiated. CHA was more potent than adenosine in this experiment and caffeine, 3 mg/kg, i.v., antagonized the effects of CHA. CHA was also found to inhibit the pressor effects of lumbar sympathetic nerve stimulation in rats while responses to intraarterial norepinephrine(NE) were potentiated. In the isolated stimulated guinea pig ileum, both CHA and adenosine inhibited the stimulation‐evoked twitches, with CHA being the more potent. Caffeine, 0.1 mM, antagonized the inhibitory effects of both compounds. CHA had no significant effect on the negative chronotropic responses to vagus nerve stimulation in dogs. These findings indicate that CHA is qualitatively similar to adenosine but is more potent and longer lasting. CHA, like adenosine, appears to alter reponses to both adrenergic and cholinergic nerve stimulation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here